RT Book, Section A1 Baljevic, Muhamed A1 Jabbour, Elias A1 Cortes, Jorge A1 Kantarjian, Hagop M. A2 Kantarjian, Hagop M. A2 Wolff, Robert A. SR Print(0) ID 1126740017 T1 Chronic Myeloid Leukemia T2 The MD Anderson Manual of Medical Oncology, 3e YR 2016 FD 2016 PB McGraw-Hill Medical PP New York, NY SN 9780071847940 LK hemonc.mhmedical.com/content.aspx?aid=1126740017 RD 2024/03/29 AB Chronic myeloid leukemia (CML) is a myeloproliferative disorder of pluripotent hematopoietic stem cells, characterized by the molecular BCR-ABL1 rearrangement, which drives a proliferative and survival advantage of the leukemic clone. About 30% to 50% of patients with CML are asymptomatic at diagnosis and are incidentally diagnosed during routine examination. Patients may also present with characteristic clinical findings secondary to large numbers of myeloid circulating progenitors, leading to splenomegaly, leukocytosis, or even isolated thrombocytosis. The landscape of CML has had a dramatic course, with a host of findings that have elucidated the biology and molecular pathology of the disease. The understanding of the molecular events led to the creation of the first targeted therapy—imatinib mesylate. Its impact on therapy and survival propelled CML as a model for modern molecular medicine in the fast-developing era of personalized targeted therapy.